ArticleThoracic cancer2025
Anlotinib Plus Osimertinib in Osimertinib-Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study.Translational lung cancer research · 2026Article
- Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).Clinical & experimental metastasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPrevious studies have shown that anlotinib plus third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) overcome acquired resistance to EGFR-TKIs in patients with advanced EGFR-mutant nonsmall cell lung cancer (NSCLC). This study aimed to retrospectively evaluate whether anlotinib plus osimertinib overcame acquired resistance in patients with nsq-NSCLC who gradually progressed after first-line EGFR-TKI treatment.
methodsThis study included patients with nsq-NSCLC who developed gradual progression after first-line osimertinib treatment, underwent an anlotinib plus osimertinib regimen in Tianjin Medical University General Hospital, and had available data from October 8, 2020 to October 14, 2023. Outcomes included the efficacy, assessed by progression-free survival (PFS), of anlotinib plus osimertinib treatment (PFS1) and prior osimertinib treatment (PFS2), to disease progression, objective response rate (ORR), disease control rate (DCR), and safety as assessed by the incidence of treatment-related toxicities.
resultsA total of 28 patients with nsq-NSCLC were included, with a median follow-up of 12 months (range, 7.8-16.2). Treatment with anlotinib plus osimertinib led to a median PFS1 of 10.0 months (95% confidence interval [CI], 8.4-11.6). With a median follow-up from prior osimertinib therapy of 31.5 months (range, 20.8-42.2), the median PFS2 was 22.0 months (95% CI, 17.5-26.5). The ORR to combination therapy was 3.6% (95% CI, 0.2-20.2) and the DCR was 85.7% (95% CI, 67.3-96.0). All patients experienced treatment-related toxicities, with 10.7% showing grade 3, and none were grade ≥ 4.
conclusionsAnlotinib plus osimertinib exhibited encouraginsg anti-tumor activity and had a manageable safety profile in patients with nsq-NSCLC showing gradual progression on osimertinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.